Neogen's (NASDAQ:NEOG) Three-year Decline in Earnings Translates Into Losses for Shareholders
Neogen's (NASDAQ:NEOG) Three-year Decline in Earnings Translates Into Losses for Shareholders
This month, we saw the Neogen Corporation (NASDAQ:NEOG) up an impressive 31%. But over the last three years we've seen a quite serious decline. In that time, the share price dropped 64%. So it is really good to see an improvement. After all, could be that the fall was overdone.
本月,我們看到紐爾真檢測公司(NASDAQ:NEOG)驚人地上漲了31%。但在過去的三年裏,我們看到了相當嚴重的下降。在那段時間裏,股價下跌了64%。所以看到這樣的改善真是好極了。畢竟,跌幅可能已經過頭了。
Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.
儘管過去一週對股東來說更令人放心,但在過去的三年中,他們仍然處於虧損狀態,因此讓我們看看基本業務是否對下降負責。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
引用巴菲特的話:“船隻將周遊世界,而‘地平派’仍會興旺。市場上的價格和價值仍會存在廣泛的差距……”考慮一家公司在市場上的認知如何變化的一個不完美但簡單的方法是比較每股收益(EPS)的變化和股價的波動。
During five years of share price growth, Neogen moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down. So given the share price is down it's worth checking some other metrics too.
在五年的股價增長中,紐爾真檢測從虧損轉入盈利。這通常被視爲一個積極因素,因此我們很驚訝看到股價下跌。因此,考慮到股價下跌,也值得檢查一些其他指標。
We note that, in three years, revenue has actually grown at a 28% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Neogen further; while we may be missing something on this analysis, there might also be an opportunity.
我們注意到,在三年內,營業收入實際上以28%的年增長率增長,因此這似乎不是出售股票的原因。也許值得進一步調查紐爾真檢測;儘管我們可能在這項分析中遺漏了一些東西,但也可能存在機會。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240608/0-2ea6c258fa61bb1ddc557ca8983eb70e-0-637209b86d1c2cf6e1a29931ca0d5809.png/big)
It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. If you are thinking of buying or selling Neogen stock, you should check out this free report showing analyst profit forecasts.
值得注意的是,上個季度我們看到了重大的內部人士買入,這被我們認爲是一個積極的信號。另一方面,我們認爲收入和盈利趨勢更是衡量業務的有意義措施。如果你正在考慮買入或賣出紐爾真檢測的股票,你應該查看這份免費報告,了解分析師的盈利預測。
A Different Perspective
不同的觀點
Neogen shareholders are down 14% for the year, but the market itself is up 25%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for Neogen that you should be aware of before investing here.
紐爾真檢測的股東今年下跌了14%,但市場本身上漲了25%。然而,請記住,即使最好的股票有時也會在12個月內跑輸市場。遺憾的是,去年的表現結束了一段糟糕的時期,股東在五年內面臨着每年8%的總虧損。總體而言,長期股價疲軟可能是一個不好的跡象,儘管逆勢投資者可能希望研究該股票以期望扭轉局面。雖然考慮市場條件對股價的不同影響非常值得,但還有其他更重要的因素。例如,我們發現了1個警告信號:在此之前,您應該了解紐爾真檢測的一些信息。
Neogen is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.
紐爾真檢測並不是唯一一個內部人士正在購買的股票。對於那些想要找到知名度較低的公司的人來說,這份最近有內部人士購入的成長型公司的免費列表可能是一個很好的選擇。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。